TCON reverse split pumpA reverse split pump in the small cap stock market refers to a situation where a company, typically with a low stock price, undergoes a reverse stock split in order to artificially inflate its stock price. Here's how it typically works:
Low Stock Price: Small cap stocks often have low prices per sh
−5.19USD
−3.59 MUSD
12.05 MUSD
2.10 M
About TRACON Pharmaceuticals, Inc.
Sector
CEO
Charles P. Theuer
Headquarters
San Diego
Website
Employees (FY)
17
Founded
2004
ISIN
US89237H3084
FIGI
BBG000R33BY8
TRACON Pharmaceuticals, Inc. engages in the development and commercialization of targeted therapies for cancer, and ophthalmic and fibrotic diseases. Its products include TRC105, an anti-endoglin antibody for the treatment of solid tumor types, TRC205 created for the treatment of fibrotic diseases, and TRC102, a small molecule that is in clinical development made for lung cancer and glioblastoma. The company was founded in October 2004 and is headquartered in San Diego, CA.
TCON - Upcoming Phase 3 Data on 03/31/2024TRACON Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing its cost efficient, contract research organization (CRO) independent product development platform to partner with ex-U.S. companies to de
TCON 1D 31% ScalpTCON 1D 31% Scalp. Followed by 76% breakout play and then 313% Swing.
TRACON Pharmaceuticals, Inc. engages in the development and commercialization of targeted therapies for cancer, and ophthalmic and fibrotic diseases. Its products include TRC105, an anti-endoglin antibody for the treatment of sol
TCON 15Min Scalpers editiontest
TRACON Pharmaceuticals, Inc. engages in the development and commercialization of targeted therapies for cancer, ophthalmic, and fibrotic diseases. Its products include TRC105, an anti-endoglin antibody for the treatment of solid tumor types; TRC205 created for the treatment of fibrotic diseases
On Balance Volume Use CasesTCON
BNGO
ONTX
$TCON daily chart. January 16 2020 traded half it's float.
March 2020 - Covid
3/16 to 8/27 Consolidation and huge block orders.
Notice how regardless of the price, OBV is climbing higher and higher steps up, 1 step back 2 steps forward. Simple addition then subtraction
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of TCON is 1.96 USD — it has decreased by 7.11% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange TRACON Pharmaceuticals, Inc. stocks are traded under the ticker TCON.
TRACON Pharmaceuticals, Inc. is going to release the next earnings report on May 15, 2024. Keep track of upcoming events with our Earnings Calendar.
TCON stock is 10.88% volatile and has beta coefficient of 1.44. Check out the list of the most volatile stocks — is TRACON Pharmaceuticals, Inc. there?
One year price forecast for TRACON Pharmaceuticals, Inc. has a max estimate of 55.00 USD and a min estimate of 20.00 USD.
TCON earnings for the last quarter are 5.80 USD per share, whereas the estimation was −1.30 USD resulting in a 546.15% surprise. The estimated earnings for the next quarter are −1.60 USD per share. See more details about TRACON Pharmaceuticals, Inc. earnings.
TRACON Pharmaceuticals, Inc. revenue for the last quarter amounts to 0 USD despite the estimated figure of 3.55 M USD. In the next quarter revenue is expected to reach 1.50 M USD.
Yes, you can track TRACON Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
TCON stock has fallen by 24.90% compared to the previous week, the month change is a 74.59% fall, over the last year TRACON Pharmaceuticals, Inc. has showed a 94.56% decrease.
TCON net income for the last quarter is 439.00 K USD, while the quarter before that showed 10.76 M USD of net income which accounts for −95.92% change. Track more TRACON Pharmaceuticals, Inc. financial stats to get the full picture.
Today TRACON Pharmaceuticals, Inc. has the market capitalization of 4.80 M, it has decreased by 53.80% over the last week.
No, TCON doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, TCON shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade TRACON Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 17.00 employees. See our rating of the largest employees — is TRACON Pharmaceuticals, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So TRACON Pharmaceuticals, Inc. technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating TRACON Pharmaceuticals, Inc. stock shows the sell signal. See more of TRACON Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on TRACON Pharmaceuticals, Inc. future price: according to them, TCON price has a max estimate of 55.00 USD and a min estimate of 20.00 USD. Read a more detailed TRACON Pharmaceuticals, Inc. forecast: see what analysts think of TRACON Pharmaceuticals, Inc. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. TRACON Pharmaceuticals, Inc. EBITDA is −6.88 M USD, and current EBITDA margin is −57.15%. See more stats in TRACON Pharmaceuticals, Inc. financial statements.